Moreover, surveying the levels of D-2-HG in a large cohort of IDH mutant glioma patients in various body fluids preoperatively, postoperatively, and through the process of treatment is needed to determine correlations, if any, with D-2-HG levels and disease burden. The gene discussed is IDH1; the disease is central nervous system cancer.